Browse

Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET

DC Field Value Language
dc.contributor.authorTseng, Jeffrey R-
dc.contributor.authorKang, Keon Wook-
dc.contributor.authorDandekar, Mangal-
dc.contributor.authorYaghoubi, Shahriar-
dc.contributor.authorLee, Joseph H-
dc.contributor.authorChristensen, James G-
dc.contributor.authorMuir, Stephen-
dc.contributor.authorGambhir, Sanjiv S-
dc.date.accessioned2010-06-25T06:55:39Z-
dc.date.available2010-06-25T06:55:39Z-
dc.date.issued2007-12-14-
dc.identifier.citationJ Nucl Med. 2008;49(1):129-134en
dc.identifier.issn0161-5505 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18077531-
dc.identifier.urihttp://jnm.snmjournals.org/cgi/reprint/49/1/129.pdf-
dc.identifier.urihttps://hdl.handle.net/10371/67813-
dc.description.abstractThe purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET. METHODS: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves. RESULTS: The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. CONCLUSION: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621.en
dc.language.isoen-
dc.publisherThe Society of Nuclear Medicine Incen
dc.subjectAnimalsen
dc.subjectAntibodies, Monoclonal/*pharmacologyen
dc.subjectAntineoplastic Agents/*pharmacologyen
dc.subjectCell Line, Tumoren
dc.subjectDrug Antagonismen
dc.subjectFluorodeoxyglucose F18/*pharmacokineticsen
dc.subjectGlioblastomaen
dc.subjectHumansen
dc.subjectMiceen
dc.subjectMice, Nudeen
dc.subjectNeoplasm Transplantationen
dc.subjectPositron-Emission Tomography/methodsen
dc.subjectProto-Oncogene Proteins c-met/*antagonists & inhibitorsen
dc.subjectRadiopharmaceuticals/*pharmacokineticsen
dc.subjectTransplantation, Heterologousen
dc.titlePreclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PETen
dc.typeArticleen
dc.contributor.AlternativeAuthor강건욱-
dc.identifier.doi10.2967/jnumed.106.038836-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse